Loading...
•
Sep 30, 2023
Celsion Q3 2023 Earnings Report
Reported a net loss, decreased operating expenses, and highlighted progress in clinical development programs.
Key Takeaways
IMUNON reported a net loss of $3.5 million for Q3 2023, a decrease from the $6.1 million loss in Q3 2022. The company highlighted progress in its clinical development programs including IMNN-001 and PlaCCine.
Reported interim data from the Phase 1/2 OVATION 2 Study showing longer PFS and OS in patients treated with a PARP inhibitor and IMNN-001.
Initiated a Phase 1/2 clinical trial in advanced ovarian cancer in combination with bevacizumab at the University of Texas MD Anderson Cancer Center.
Confirmed the versatility of the PlaCCine modality by demonstrating preclinically the immunogenicity and safety of vaccines against multiple pathogens.
Advanced the development of DNA infectious disease vaccines with preclinical demonstration of more durable antigen expression and T-cell responses.